[go: up one dir, main page]

WO2017095918A3 - Procédés de traitement du cancer au moyen d'antagonistes de rspo3 - Google Patents

Procédés de traitement du cancer au moyen d'antagonistes de rspo3 Download PDF

Info

Publication number
WO2017095918A3
WO2017095918A3 PCT/US2016/064207 US2016064207W WO2017095918A3 WO 2017095918 A3 WO2017095918 A3 WO 2017095918A3 US 2016064207 W US2016064207 W US 2016064207W WO 2017095918 A3 WO2017095918 A3 WO 2017095918A3
Authority
WO
WIPO (PCT)
Prior art keywords
rspo3
methods
antagonists
treating cancer
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/064207
Other languages
English (en)
Other versions
WO2017095918A2 (fr
WO2017095918A4 (fr
Inventor
Ann M. Kapoun
Chun Zhang
Min Wang
Yu-Wang Liu
Gilbert O'YOUNG
Fiore CATTARUZZA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomed Pharmaceuticals Inc
Original Assignee
Oncomed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals Inc filed Critical Oncomed Pharmaceuticals Inc
Publication of WO2017095918A2 publication Critical patent/WO2017095918A2/fr
Publication of WO2017095918A3 publication Critical patent/WO2017095918A3/fr
Publication of WO2017095918A4 publication Critical patent/WO2017095918A4/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions permettant d'identifier des tumeurs susceptibles de répondre à un traitement avec un antagoniste de RSPO3 (par exemple un anticorps anti-RSPO3). L'invention concerne également des procédés d'identification de tumeurs et/ou de patients qui sont susceptibles de répondre ou de ne pas répondre au traitement avec un antagoniste de RSPO3 (par exemple un anticorps anti-RSPO3). L'invention concerne en outre des procédés de traitement d'un patient atteint d'un cancer, lorsqu'il est prévu que le cancer réponde à un antagoniste de RSPO3 (par exemple un anticorps anti-RSPO3).
PCT/US2016/064207 2015-12-01 2016-11-30 Procédés de traitement du cancer au moyen d'antagonistes de rspo3 Ceased WO2017095918A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562261618P 2015-12-01 2015-12-01
US62/261,618 2015-12-01
US201662308577P 2016-03-15 2016-03-15
US62/308,577 2016-03-15

Publications (3)

Publication Number Publication Date
WO2017095918A2 WO2017095918A2 (fr) 2017-06-08
WO2017095918A3 true WO2017095918A3 (fr) 2017-07-13
WO2017095918A4 WO2017095918A4 (fr) 2017-08-31

Family

ID=58797679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/064207 Ceased WO2017095918A2 (fr) 2015-12-01 2016-11-30 Procédés de traitement du cancer au moyen d'antagonistes de rspo3

Country Status (1)

Country Link
WO (1) WO2017095918A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339364B (zh) * 2018-04-02 2021-02-12 上海邦耀生物科技有限公司 Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗
WO2021080396A1 (fr) * 2019-10-24 2021-04-29 가톨릭대학교 산학협력단 Composition pour la prévention ou le traitement d'une cardiopathie valvulaire comprenant un inhibiteur de rspo3

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100357A2 (fr) * 2005-10-07 2007-09-07 Nuvelo, Inc. Scfa1, protéine du type facteur des cellules souches et utilisations de celle-ci
US20070244061A1 (en) * 2003-10-10 2007-10-18 Deutsches Krebsforschungszentrum Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondisn) and/or Wnt
WO2012178058A1 (fr) * 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Compositions et méthodes de détection, de diagnostic et de pronostic du cancer du thymus
WO2013120056A1 (fr) * 2012-02-11 2013-08-15 Genentech, Inc. Translocations de r-spondine et leurs procédés d'utilisation
WO2014165232A1 (fr) * 2013-03-12 2014-10-09 Curegenix, Inc. Composés pour le traitement du cancer
WO2015058132A2 (fr) * 2013-10-18 2015-04-23 Genentech, Inc. Anticorps anti-rspo et leurs méthodes d'utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244061A1 (en) * 2003-10-10 2007-10-18 Deutsches Krebsforschungszentrum Compositions for Diagnosis and Therapy of Diseases Associated with Aberrant Expression of Futrins (R-Spondisn) and/or Wnt
WO2007100357A2 (fr) * 2005-10-07 2007-09-07 Nuvelo, Inc. Scfa1, protéine du type facteur des cellules souches et utilisations de celle-ci
WO2012178058A1 (fr) * 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Compositions et méthodes de détection, de diagnostic et de pronostic du cancer du thymus
WO2013120056A1 (fr) * 2012-02-11 2013-08-15 Genentech, Inc. Translocations de r-spondine et leurs procédés d'utilisation
WO2014165232A1 (fr) * 2013-03-12 2014-10-09 Curegenix, Inc. Composés pour le traitement du cancer
WO2015058132A2 (fr) * 2013-10-18 2015-04-23 Genentech, Inc. Anticorps anti-rspo et leurs méthodes d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SESHAGIRI, S ET AL.: "Recurrent R-spondin fusions in colon cancer", NATURE LETTER., vol. 488, no. 7413, 30 August 2012 (2012-08-30), pages 660 - 664, XP055060432 *

Also Published As

Publication number Publication date
WO2017095918A2 (fr) 2017-06-08
WO2017095918A4 (fr) 2017-08-31

Similar Documents

Publication Publication Date Title
WO2016109782A3 (fr) Méthodes et compositions pour la détection de néoplasies colorectales
IL264156A (en) Compounds, preparations and methods for treating the disease
EP3481402A4 (fr) Composés, compositions et méthodes de traitement de maladie
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
WO2014153030A3 (fr) Méthodes de traitement du cancer et de prévention d'une résistance à un médicament anticancéreux
WO2017181079A3 (fr) Méthodes de surveillance et de traitement du cancer
FI20145492A7 (fi) Menetelmä Parkinsonin taudin diagnostiikkaan, hoitoon ja estämiseen
WO2015164392A8 (fr) Nouveaux anticorps antii-rnf43 et méthodes d'utilisation
WO2014138364A3 (fr) Méthodes de traitement et de prévention de la résistance à un médicament d'un cancer
EP3212658A4 (fr) Analogues de 2',2'-dihalo-nucléosides utilisables en vue du traitement d'infections par des virus de la famille des flaviviridae et du cancer
WO2015171558A3 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
WO2016066634A3 (fr) Utilisation d'antagonistes du ccr5 en monothérapie ou en polythérapie pour le traitement du cancer
WO2017066712A3 (fr) Modulateurs de maladie de télomères
WO2016057683A3 (fr) Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci
SG11201705450SA (en) Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
WO2013106747A3 (fr) Méthodes et compositions pour le traitement et le diagnostic du cancer de la thyroïde
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
WO2017066796A3 (fr) Modulateurs de maladies impliquant des télomères
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2020000135A (es) Nuevos compuestos de quinolinona.
WO2017181163A3 (fr) Méthodes et compositions pour la détection et le diagnostic du cancer du sein
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MA42611A (fr) Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16871418

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16871418

Country of ref document: EP

Kind code of ref document: A2